Our Science. Your Life.
Medicane R&D Partnerships
Chief Financial Officer
Noam is a certified CPA and a Bar Association member. Currently, Noam serves as the CFO at MediCane Health Incorporated group, overseeing financial strategy, planning, and analysis. His prior roles include Financial Controller and FP&A Manager. Noam holds a Bachelor’s degree in Law and Business Management with a major in Accounting from the IDC-Herzliya.
CEO, MediCane R&D
Tweezer-Zaks is an experienced Healthtech, Biotech and Pharma Executive, encompassing scientific, clinical, and commercial proficiencies across all therapeutic areas. Situated at the junction of clinical medicine (as a specialist in Internal Medicine and Rheumatology), Science (researcher and former fellow at the NIH- the national Institutes of Health USA) and business, Nurit held various executive position in a global pharmaceutical corporation (Sanofi), particularly in the external innovation area, identifying, assessing and internalizing innovation into the company’s pipeline, and in a leading Venture Capital Fund investing globally both in early stage as well as growth stage companies in the life sciences. Nurit translates her expertise in the crossroads of Medicine, Science and Business to advance interesting technologies to maturity. Currently, Nurit is the CEO of an early-stage drug development company, MediCane R&D. Nurit is also an Instructor at the Hebrew University (MD-MBA program), a consultant to companies at various stages of development, a certified business arbitrator and serves as Director and Independent Director in boards of private and public companies.
Dr. Koren is the founder and CEO of SciCann Therapeutics Inc., a speciality pharma company dedicated to the development of cutting-edge therapies for cancer and inflammatory diseases in the pharmaceutical cannabinoid space. Dr. Koren is also the co-founder and CTO of Xinteza API, an R&D company developing disruptive biosynthesis production technologies for pure, pharma-grade, cannabinoid, and psychedelic APIs. Xinteza is based on scientific discoveries made by Prof. Asaph Aharoni, head of the plant metabolomics lab. in the Weizmann institute of Science in Rehovot, Israel. Dr. Koren holds a Ph.D. and M.Sc. in life sciences and computational biology from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. Dr. Koren is a veteran of the prestigious “Talpiyot” program of the Israeli Defense Forces, an elite unit designed to qualify the top technology officers of the IDF.
Procurement, Budget, and Logistics Manager
Veronica brings over 15 years of experience in procurement and project management working in global organizations and in multi-task, multi-interface environments. She has managed budgets at a scope of Millions of USD and has worked with multiple supply chains, import and export lineups, vendors, and authorities. Veronica holds a B.A. degree in Economy & Management and an M.A. in Behavioral science.
Project manager & Clinical Research Associate
Adi is an experienced research project manager with over 16 years of experience in development, conduction, and management of various clinical research initiatives, in a multidisciplinary environment. Adi holds a B.Sc. in Biology and an M.Sc. in Biochemistry and Molecular Biology from the Tel Aviv University and is a certified CRA.
Senior Scientist, Head of Cosmetics Unit, and Formulator
Hagay Moshe manages the scientific development of formulations for various purposes and applications in product manufacturingand is involved in identifying potential partners for mutually beneficial strategic alliances especially in the field of cosmetics. During his career, he worked in R&D positions in several start-up companies. He has over 15 years of broad expertise heading R&D projects, inventing formulations, synthesizing materials, and scaling up processes. He holds a PhD in Chemistry at the Department of Chemistry and Institute for Nanotechnology and Advanced Materials Bar-Ilan University.
Neta Rimmerman completed her PhD studies in Psychology and Neuroscience at Indiana University (USA) and her Post-doctoral training in the Department of Neurobiology at the Weizmann Institute of Science in Israel. Dr. Rimmerman held a faculty research position at the Hebrew University of Jerusalem and is one of the world’s veteran cannabis scientists, with 16 years of experience researching cannabinoids with focus on pain.
Head of Global Regulatory Affairs
Talma Gotteiner is a Regulatory Affairs Expert with over 20 years of experience in the pharmaceutical industry. During her career, she worked in clinical and regulatory positions in several pharmaceutical start-up companies. Dr. Gotteiner has experience in developing regulatory strategies and leading registration projects and teams in the industry. She has worked with regulatory authorities, agencies, and scientific committees worldwide, including the FDA and EMA. She holds a PharmD from the Hebrew University and is RAC-US certified by the Regulatory Affairs Professionals Society (RAPS).
Mrs. Matar is an experienced and dedicated executive lawyer and legal consultant specialized in working in global companies. Yael gained special expertise in day-to-day legal counseling to all units of a company, commercial transactions, strategic alliances, corporate, labor, intellectual property, compliance, and regulation. Mrs. Matar is an international lawyer licensed in Israel (2004), holds LL.B (with Distinct Honors) and LL.M (with excellence) from Tel Aviv University.
Tzahi Mor is an entrepreneurial manager with excellent problem-solving abilities offering broad-based experience in Accounting and Finance along with a strong negotiation skills and business acumen. For the past 13 years Tzahi have specialized in building and managing financial teams in international large companies and international start-ups. leading the implementation of financial ERP systems, financial reporting, and financial planning, as well as BI systems for day-to-day management and global taxation strategies.
Tzahi holds a B.A in accounting and economics from the Hebrew university, and MBA in financial management from Tel Aviv university.
Tzahi lives in Israel with his wife Maayan and his two children.
Chief Operation Officer
Yoav Nir holds BBA in Business administration, Management, and international finance. He served as a CEO, Managing Director and VP operation in multi-national and public companies in the field of Agriculture, wellness, food supplements, cosmetics, and health industry. he has a deep and wide knowledge and understanding in all of business aspects and working with health authorities, strict regulations and quality control system and standards. Yoav brings over 25 of years of wealth of experience and knowledge in the agriculture business and working as an expert for various agriculture projects and served as the COO of the largest growing and export flower, vegetable, and fruits company in Israel and managed 100 hectares of flower’s farm in Kenya-East Africa. For the last 5 years he is highly involved in the medical cannabis industry in all the aspects from regulation & legalization process, planning, establishing, and managing projects in the fields to final products developmentg and marketing.
An entrepreneur with experience in building companies from early stage, leading companies for a long terms’ success, by creating, developing, and implementing the company vision and strategy.
Full-time position-regular working hours
Location in Kfar Saba
Directly reporting to the company’s Finance Director
Role requirements and previous experience:
Level 3 in accounting
3-5 years of experience
Experience in authorities’ submissions VAT and Tax
Proven experience and capabilities in performing “month-end closing” to the level of “balance closing”.
Experience working with ERP systems Priority \ NetSuite \ SAP
Ability to write and communicate in English, at a high level
Reports to VP R&D
M.H MediCane is looking for a senior clinical program manager to manage all of MediCane’s clinical program aspects
The requirements listed below are representative of the knowledge, skill, and abilities required:
Knowledge, Skills, and Abilities:
Operator/technician at a cannabis manufacturing plant
Partner in the process of establishing a pharmaceutical production system
Executing productions and packaging
Working in a pharmaceutical manufacturing environment, under GMP conditions, according to quality procedures and working instructions
Operation of manufacturing and packaging machines, integrated automation, and computerized control.
Perform all tasks in manufacturing processes from raw materials to final product shipping Logistics – absorption of raw materials, issue to the factory, absorption, and management of inventory in the process and finished produce.
Operating workstations according to work procedures and instructions
Performing and documenting manufacturing operations according to GMP requirements
Closing the workstations and preparing the rooms and equipment for further production.
Working Experience within pharmaceutical production systems
Performing the role of the operator in Pharma manufacturing production floor
Ability to follow procedures and follow working instructions in a GMP environment.
writing and documentation
Managing documentation – Documents Knowledge as diverse as possible in manufacturing equipment, support systems (water, gases, HVAC)
English at Entry-level
Ability to perform a wide variety of roles from different professions in the production system
We are looking for a global quality assurance manager for the company, operating in the field of pharma – medical cannabis. Reporting to the company COO.
Overall responsibility for all quality assurance aspects and activities in manufacturing and research and development, in Israel and abroad.
Leading the company Global QA team.
Responsibility for developing and implementing quality systems on the various sites, managing ongoing control, building training and certificate systems.
B.A. in Life Sciences/Engineering/ Industry and Management/Quality.
Proven experience of at least 5 years in developing and managing global quality assurance systems at GMP certified sites from the pharma industry.
Experience in GMP reviews.
English – high-level.
Mr. Sapir is a CPA with over 23 years of financial management experience including strategic planning, IPO, mergers, and acquisitions, budget planning and control, treasury and accounting, as well as US securities law compliance issues. Mr. Sapir has vast experience in leading companies through growth, complex restructuring, international expansion, and capital markets transactions. Prior to joining MediCane, Mr. Sapir was a CFO in a variety of companies, such as Wavion, where he led the acquisition of the company by Alvarion (NASDAQ: ALVR), and Allot Communications (NASDAQ: ALLT), where he led the IPO on NASDAQ. Mr. Sapir holds a B.A. in Accounting and Economy from the Tel Aviv University, and M.B.A in Finance and Capital Markets (cum laude) from Ono Academic College.
Chair of the Scientific Advisory Board
Dr. Weiner studied Organic Chemistry at the Hebrew University of Jerusalem, completed his Ph.D. in Chemistry in 1972, and had his postdoctoral fellowship training at Schering-Plough Corporation in the United States. He started working in Teva Pharmaceuticals in 1975, and since then served in various prominent R&D positions, including VP R&D and Senior Global VP R&D. He was granted the Rothschild Prize for Industrial Innovation twice: in 1989 for the development of Alpha D3 for kidney and bone disorders, and in 1999 for the development of Copaxone(R) for multiple sclerosis. During his 37-year career at Teva, Dr. Weiner was responsible for the introduction and FDA approvals of numerous products in the U.S. and other countries, including “simple” generics, value added generics and bio-similar biologic product development. Under his leadership multiple innovative products were developed and later on launched worldwide, including Copaxone(R) for multiple sclerosis (with billions of dollars peak sales a year), Azilect for Parkinson’s disease, and many others. Dr. Weiner retired from Teva in 2012, and currently holds scientific advisory board positions in various pharmaceutical companies.
Co-founder & Active Chairman
Successful entrepreneur, who co-founded Mobileye in 1999 and served as its President and CEO. Mobileye became a leading AutoTech company, which in 2017 was acquired by Intel for $15.3B – the biggest ever acquisition of an Israeli company. In 2010, Mr. Aviram also co-founded OrCam, and currently serves as the company’s Co-chairman, President and Co-CEO. OrCam harnesses AI-driven computer vision to provide increased independence to people who are blind or visually impaired, are hearing impaired, have reading difficulties, and for other populations.
Co-founder & CEO
Senior pharma executive with over 30 years of experience in both research-based and generic companies. During the past 22 years Mr. Ben Amram held senior positions at MSD, which included SVP & Pres. of Europe, Russia, Middle East and Africa, SVP & Pres. of Diversified Brands Division, SVP & General Manager of Emerging Markets Region, and Global Franchise VP for Asthma Products. Prior to that he held several key positions in Teva Pharma.
Co-founder & CSO
An Israeli lawyer with a dynamic career of over 25 years, during which he has acted as a litigator in major cases, along with establishing activities focusing on commercial and civil matters at Amnon Zichroni & Co. Later, Mr. Greenspoon held a boutique practice, actively serving as legal adviser and member of the Board of Mobileye. He is the CEO of a real estate development company in Israel, responsible for commercial projects above 200,000 sq. m. He is also a member of the Board of OrCam and the owner of Halilit – a musical instrument distributor in Israel.
Professor of Neuroscience and Neurology: Director and CEO of Zuckerman Mind Brain Behavior Institute, Columbia University
Prof. Costa received his D.V.M. from the University of Lisbon. He completed his Ph.D. studies with Dr. Alcino Silva at UCLA followed by postdoctoral work with Dr. Miguel Nicolelis at Duke University. Prof. Costa became a Section Chief at the National Institutes of Health in 2006, and in 2009 became an Investigator of the Champalimaud Neuroscience Program. From 2011 to 2013 he served as Deputy Director, and from 2014 to 2017 – as Director of Champalimaud Research.
Prof. Costa uses genetic, electrophysiological, optical, and behavioral approaches to investigate the mechanisms underlying the generation and learning of novel actions. He also studies disorders that lead to problems with action initiation, compulsive behaviors, and habits. He has received the Young Investigator Award from the Society for Neuroscience and the Jean-Louis Jeantet Foundation, the Ariëns Kappers Medal from the Royal Netherlands Academy of Arts and Sciences and was knighted Commander of the Order of Sant’Iago da Espada. He is an elected member of EMBO and the National Academy of Medicine.
Professor of Psychological and Brain Sciences, Indiana University Bloomington
Prof. Bradshaw completed her B.Sc. in Nutrition and PhD in Neuroscience at Florida State University with focus on peripheral inflammation and visceral pain across the hormonal cycle. She completed her postdoctoral studies at Brown University investigating the role of the endocannabinoid system in pain and inflammation and is currently a Professor of Psychological and Brain Sciences at Indiana University. Her research combines the fields of neurophysiology, behavior, and lipid biochemistry to understand how lipid signaling drives changes in cellular communication.
Prof. Bradshaw’s work demonstrated that lipoamines and related lipids, prostaglandins, are differentially regulated by each of the enzymes and receptors associated with the endogenous cannabinoid system and that the active compounds in Cannabis, THC and CBD, likewise regulate these classes of lipids. Prof. Bradshaw serves on the International Cannabinoid Research Society board since 2016 and was recently elected as the ICRS liaison to and Associate Editor for the Cannabis and Cannabinoid Research journal.
Director of Clinical Neurosciences at St. Vincent’s Hospital, Melbourne: Chair of Medicine at the University of Melbourne
Prof. Cook is the Director of Clinical Neurosciences at St. Vincent’s Hospital, as well as the Director of the Graeme Clark Institute and the Sir John Eccles Chair of Medicine at the University of Melbourne. After completing specialist training in Melbourne, he undertook an M.D. thesis while working as Brain Research Fellow at Queen Square, London. He returned to St. Vincent’s Hospital to continue his interest in neuroimaging and management of complex epilepsy.
Prof. Cook specializes in the treatment of epilepsy and is recognized internationally for his expertise in epilepsy management, particularly imaging and surgical planning. He has worked closely with engineers for most of his career, developing novel therapies for epilepsy. His interests have included experimental models of epilepsy and seizure prediction, and he has led the commercialization of an implantable seizure detection device about to start clinical trials.
Professor of Pathology and Cell Biology, Columbia University Erving Medical Center
Dr. Israely carried out her PhD research at the University of California, Los Angeles, in the laboratory of Drs. Xin Liu and Alcino Silva, where she demonstrated that loss of a neural specific cell adhesion protein linked to disease, delta-catenin, results in cognitive dysfunction. Dr. Israely joined Dr. Susumu Tonegawa’s lab at MIT for her postdoctoral training, where she used two-photon imaging and glutamate uncaging to uncover the learning rules associated with long lasting structural and functional changes at individual synapses. In 2009, she started her own group at the Champalimaud Foundation, and in 2016, the lab relocated to Columbia University, in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, within the departments of Pathology and Cell Biology and Neuroscience. She uncovered dynamic interactions between spines during synaptic plasticity, such as cooperation and competition, that are critical for the long term storage of information in the brain. Dr. Israely’s laboratory uses genetic, electrophysiological, optical and molecular approaches to study how activity dependent structural changes shape neural circuits, and how when impaired, these contribute to neurodevelopmental disorders, including autism, and neurodegeneration.
Head of Human Resources
Mr. Netzer is an HR expert with over 30 years of experience in establishing people-centric organizations in global, cross-cultural settings. Previously, he held a variety of senior executive positions at Teva, where he served as organizational advisor and business partner to top executives and was involved in major corporate transformations. He specializes in change management, M&A and cross-cultural strategies, coaching and mentoring. He holds a B.A.in Human Behavior from Ben Gurion University and an M.B.A. in Business Administration from the Hebrew University of Jerusalem.
Head of Marketing & sales
Ms. Balaban is a marketing specialist with hands-on experience in a variety of management positions in the pharmaceutical field. As the former Manager of the Medical Cannabis Marketing Segment at Teva, she brings significant expertise in regulatory and government affairs, as well as in facilitating and establishing an infrastructure to support the launching, marketing, sales and distribution of prescription medications. She holds a B.Sc. in Biochemistry from Ben Gurion University.
Ms. Shaul-Shalem is a legal expert and a public notary with a comprehensive experience in providing legal consulting services to corporate clients in the medical, pharmaceutical and biotechnological industries. She specializes in commercial law, business and human resource matters, commercial procurement activities, compliance, negotiations with regulatory agencies, and global third-party partnerships. She holds an L.L.B. in Law Studies and a B.A. in Business Administration from the Herzliya Interdisciplinary Center, and an L.L.M. in Law Studies from Bar Ilan University.
Global Supply Chain Lead
Mr. Codner is MediCane’s Distribution Director since April 2019 with an extensive background in pharmaceuticals, finance, and logistics. Richard is the former Executive Director of Global Market Access at Merck, Sharp, and Dohme (MSD). He served as MSD’s European Director of Distribution 12 years. Earlier he was a Finance Director at 3M. He is a CPA in the state of California and in Israel with experience in tax and audit at KMPG in his native Los Angeles. Richard earned a magna cum laude BA in Psychology at Brown University and an MBA at University of Southern California.
Mr. Quodt is a health care adviser with over 35 years of comprehensive experience working in the research-driven pharmaceutical industry in senior executive positions across Europe and the U.S. During his career he also served as chairman/co-chairman of national pharmaceutical associations. Currently he is advising investment groups and start-up ventures in the health care, food and consumer goods industry. He holds a degree in Business Administration and Market Psychology from the University of Munich, Germany.
CEO MediCane Portugal
Mrs. Broder-Koshet is an experienced strategic and marketing planning specialist with expertise in devising and implementing business strategies in global markets. As former Marketing Manager at AT&T Israel, she has a strong background in handling large budgets and establishing corporate partnerships in a variety of countries. She holds a B.Sc. in International Business Administration from the American College of Switzerland, and an M.Sc. in Business Management from Boston University.
CEO MediCane Australia
Mr. Katz is a former Asia Pacific CEO of a leading international FMCG retailer, with vast global management experience in diverse service and retail business units. He is a qualified lawyer and has held senior positions and advisory roles in the fields of management consulting, general management, retail leasing, franchising and corporate strategy for local and global organizations. He holds a bachelor’s degree in law and a B. Comm. (Honours) from the University of Cape Town.